New monoclonal antibodies for female genital tract pathology

news November 14 2022

Atlas Antibodies has released new PrecisA MonoclonalTM antibodies targeting 23 proteins relevant to ovarian cancers (such as high and low-grade serous, endometrioid, clear cell, and mucinous carcinomas), with diagnostic and prognostic values validated in IHC, WB, and ICC-IF.

Early detection of ovarian cancer would improve the 5-year survival rate, from close to 90% in stage I compared to only 20% when the cancer is discovered in stage IV.

Find a vast catalog of highly validated monoclonal antibodies targeted for cancer research here.

Browse monoclonal antibodies targeted for cancer research

Subscribe to our newsletter

Get the latest news within your area of research to your inbox.
Subscribe →